Investors

Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update

Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 11, 2020

Received FDA Acceptance of LIQ861 NDA for Review
Reported Final Safety and Tolerability Results for LIQ861 Inspire Trial
Management to Host Webcast and Conference Call Today at 4:30p.m. ET

RESEARCH TRIANGLE PARK, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

"FDA acceptance of the LIQ861 NDA for review is a significant milestone and a testament to the progress we have made as a company, including our ability to harness the power of our PRINT technology to advance our product candidates through clinical development,” said Neal Fowler, Chief Executive Officer of Liquidia. “If approved, LIQ861 represents an important step forward for patients in need of additional treatment options and will serve as the gateway for Liquidia to achieve its goal of becoming a fully integrated, commercial organization. I am proud of the progress we have made as a company on all fronts, even in the face of a global crisis, and remain confident in our approach toward our 2020 objectives.”

Corporate Update

  • Received FDA acceptance of LIQ861 NDA for regulatory review
    In January 2020, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LIQ861, the Company’s lead product candidate, as a potential treatment for patients with pulmonary arterial hypertension (PAH). In April 2020, the FDA accepted the NDA for review and provided a Prescription Drug User Fee Act (PDUFA) goal date of November 24, 2020Liquidia is developing LIQ861 under the 505(b)(2) regulatory pathway with Tyvaso® as the reference listed drug, which allows Liquidia to rely in part on the FDA’s previous findings of efficacy and safety of Tyvaso and the active ingredient treprostinil, which has been approved in four different products administered through the oral, inhaled and continuous infusion (parenteral) routes.

  • Reported final LIQ861 safety and tolerability results from pivotal INSPIRE trial
    In April 2020, the Company reported final safety and tolerability results from the two-month endpoint of the open-label phase 3 trial, INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, for LIQ861.  Of the 121 PAH patients, 113, or 93 percent, completed their two-month visit. The most common reported treatment-emergent adverse events (TEAEs) (reported in ≥ four percent) were cough (42 percent), headache (26 percent), throat irritation (16 percent), dizziness (11 percent), diarrhea (9 percent), chest discomfort (8 percent), nausea (7 percent), dyspnea (5 percent), flushing (5 percent) and oropharyngeal pain (4 percent). These final primary endpoint findings are consistent with the safety and tolerability results previously reported.

  • Initiated inter partes review of two patents with Patent Trial and Appeal Board
    In late March 2020, Liquidia filed two petitions for inter partes review with the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO). One petition is for inter partes review of U.S. Patent No. 9,604,901, and a second petition is for inter partes review of U.S. Patent No. 9,593,066, both of which are owned by United Therapeutics Corporation, or United Therapeutics, are entitled “Process to Prepare Treprostinil, the Active Ingredient in Remodulin®” and are related to the LIQ861 505(b)(2) NDA submission. A determination by the PTAB to institute the petitions is expected before the end of the third quarter of 2020, and a final written decision determining the validity of the challenged claims of the ‘066 patent and the ‘901 patent, if the petitions are instituted by the PTAB, is expected within 12 months from institution.

First Quarter 2020 Financial Results

Research and development expenses were $10.8 million for the three months ended March 31, 2020, which approximated the amount recognized of $10.7 million for the three months ended March 31, 2019. Research and development expenses for consulting costs increased by $1.2 million during the first quarter of 2020 compared with the first quarter of 2019. This increase was primarily offset by a decrease of $0.8 million from the reclassification of costs for efforts to prepare for potential commercialization and certain insurance costs to general and administrative expenses during the first quarter of 2020 compared with the first quarter of 2019.

General and administrative expenses were $3.8 million for the first quarter of 2020, compared with $3.0 million for the first quarter of 2019. The increase of $0.8 million, or 26.5 percent, was primarily due to a reclassification of costs for efforts to prepare for potential commercialization and certain insurance costs to general and administrative expenses from research and development expenses during the first quarter of 2020 compared with the first quarter of 2019.

Interest income was $0.1 million for the first quarter of 2020, which approximated interest income of $0.1 million during the first quarter of 2019. 

Interest expense was $0.3 million for the first quarter of 2020, compared with $0.2 million for the first quarter of 2019, primarily due to higher levels of debt during the first quarter of 2020 as compared with the first quarter of 2019.

Net loss was $14.8 million for the first quarter of 2020, compared with $13.8 million for the first quarter of 2019. The increase of $1.0 million, or 7.4 percent, was primarily due to an increase in research and development consulting costs during the first quarter of 2020 compared with the first quarter of 2019.

Cash and cash equivalents totaled $40.1 million as of March 31, 2020. There were 28.4 million shares outstanding as of March 31, 2020.

Webcast and Conference Call

The Liquidia Management Team will host a webcast and conference call at 4:30 p.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-877-707-8711 (domestic) and 1-857-270-6219 (international) and entering the conference code: 1438598. A live and archived webcast of the call will be available on the Events & Presentations page of Liquidia’s website.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Forward-Looking Statements

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related timelines, including potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for LIQ861, the timeline related to our two petitions for inter partes review with the Patent Trial and Appeal Board, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the Securities and Exchange Commission, including the impact of the coronavirus (COVID-19) outbreak on our company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

-Financial Tables Follow-


Liquidia Technologies, Inc.
Balance Sheets
  March 312020   December 31, 2019
Assets        
Current assets:        
Cash $ 40,127,919   $ 55,796,378  
Prepaid expenses and other current assets   884,923     590,251  
Total current assets   41,012,842     56,386,629  
Property, plant and equipment, net   8,599,985     9,253,965  
Operating lease right-of-use assets, net   2,785,238     2,823,430  
Prepaid expenses and other assets   381,043     378,043  
Total assets $ 52,779,108   $ 68,842,067  
Liabilities and stockholders’ equity        
Current liabilities:        
Accounts payable $ 5,530,526   $ 3,498,043  
Accrued compensation   1,428,270     3,164,687  
Accrued stock offering expenses       1,289,413  
Other accrued expenses   1,463,772     1,525,919  
Current portion of operating lease liabilities   589,931     566,390  
Current portion of finance lease liabilities   1,484,882     1,244,229  
Current portion of long-term debt   5,585,636     5,585,637  
Total current liabilities   16,083,017     16,874,318  
Long-term operating lease liabilities   5,512,485     5,670,971  
Long-term finance lease liabilities   511,809     1,056,747  
Long-term debt   8,899,877     10,292,484  
Total liabilities   31,007,188     33,894,520  
Commitments and contingencies        
Stockholders’ equity:        
Common stock — $0.001 par value, 40,000,000 shares authorized as of March 31, 2020 and December 31, 2019, 28,368,698 and 28,231,267 issued and outstanding as of March 31, 2020 and December 31, 2019, respectively   28,368     28,231  
Additional paid-in capital   251,774,481     250,158,766  
Accumulated deficit   (230,030,929 )   (215,239,450 )
Total stockholders’ equity   21,771,920     34,947,547  
Total liabilities and stockholders’ equity $ 52,779,108   $ 68,842,067  

Liquidia Technologies, Inc.
Statements of Operations and Comprehensive Loss

    Three Months Ended
    March 31,
    2020     2019  
Revenues $   $  
Costs and expenses:        
Research and development   10,822,924     10,664,302  
General and administrative   3,823,197     3,021,581  
Total costs and expenses   14,646,121     13,685,883  
Loss from operations   (14,646,121 )   (13,685,883 )
Other income (expense):        
Interest income   109,590     137,785  
Interest expense   (254,948 )   (218,691 )
Total other income (expense), net   (145,358 )   (80,906 )
Net loss   (14,791,479 )   (13,766,789 )
Other comprehensive income (loss) $   $  
Comprehensive loss   (14,791,479 )   (13,766,789 )
Net loss per common share:        
Basic $ (0.52 ) $ (0.86 )
Diluted   (0.52 )   (0.87 )
Weighted average common shares outstanding:        
Basic   28,428,616     16,037,767  
Diluted   28,322,342     15,892,619  
Contact Information

Media:
Michael Parks
Corporate Communications
484.356.7105
michael.parks@liquidia.com

Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

LIQUIDIA_Logo.jpg

Source: Liquidia Technologies, Inc.